Now, a number of biomarkers in non-small-cell lung cancer (NSCLC) are being tested in routine diagnostics, including EGFR and BRAF mutations, as well as ALK and ROS1 rearrangements and PD-L1 expression [1]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.